Mastropasqua L, Carpineto P, Ciancaglini M, Zuppardi E, Lobefalo L, Gallenga P E
University G.D'Annunzio, Chieti, Italy.
Eye (Lond). 1998;12 ( Pt 4):701-6. doi: 10.1038/eye.1998.172.
The current study was performed to evaluate the efficacy and safety of late post-operative use of subconjunctival 5-fluorouracil (5-FU) with ocular massage (OM) after trabeculectomy with or without intraoperative mitomycin C (MMC) in patients with medically uncontrolled primary open angle glaucoma (POAG).
Initial trabeculectomy was performed in 60 eyes of 60 consecutive patients with medically uncontrolled POAG. Thirty eyes (group 1) were randomly assigned to intraoperative MMC (0.2 mg/ml for 3 min) and 30 (group 2) were randomised to standard trabeculectomy. During the first 3 months post-operatively OM and subconjunctival injections of 5-FU (5 mg in 0.5 ml of balanced salt solution) were performed in both groups every time the clinical evaluation suggested imminent bleb failure. Suture lysis was not performed in any patient.
Follow-up ranged from 14 to 53 months (mean 30.17, SD 9.23) in trabeculectomy + MMC treated eyes and from 6 to 54 months (mean 27.37, SD 10.83) in trabeculectomy treated eyes. During the first 3 months of follow-up OM and subconjunctival injections of 5-FU were performed in 14 cases in group 1 and in 18 cases in group 2 (p = NS). A positive response to OM was obtained in 14 of 14 eyes and in 14 of 18 eyes in group 1 and in group 2, respectively (p = 0.042). The difference in post-operative mean IOP between the two groups was statistically significant at each time interval studied (p < 0.001). Success (complete or qualified) was achieved in 50 of 60 eyes (83.33%): 28 (93.3%) in the trabeculectomy + MMC treated group and 22 (73.3%) in the trabeculectomy treated group (p = 0.039). Among the complications seen, the incidence of bleb fibrosis was higher in group 2 (p = 0.0026). By means of post-operative treatment four nonrandomised subgroups were identified: intraoperative MMC + post-operative 5-FU, intraoperative MMC + no post-operative 5-FU, no intraoperative MMC + post-operative 5-FU, no intraoperative MMC + no post-operative 5-FU. The eyes treated with intraoperative MMC and post-operative 5-FU had a better long-term (48 months) cumulative probability of success (100%); treatment with intraoperative MMC or post-operative 5-FU alone was followed by a success rate of 87.1% and 72.2%, respectively. The cumulative probability of success after only trabeculectomy was 56% (p < 0.05). One case of hypotony maculopathy was found in the subgroup treated only with intraoperative MMC.
This study confirms the effectiveness and relative safety of delayed post-operative 5-FU treatment in patients with clinical evidence of bleb failure. Only when OM had caused a lowering of IOP were late subconjunctival injections of 5-FU followed by good control of IOP. The use of intraoperative MMC may ensure a greater IOP decrease after OM.
本研究旨在评估在原发性开角型青光眼(POAG)药物治疗效果不佳的患者中,小梁切除术中使用或不使用术中丝裂霉素C(MMC)后,结膜下注射5-氟尿嘧啶(5-FU)并联合眼部按摩(OM)的术后晚期疗效和安全性。
对60例连续的药物治疗效果不佳的POAG患者的60只眼睛进行初次小梁切除术。30只眼睛(第1组)随机分配接受术中MMC(0.2mg/ml,持续3分钟),另外30只眼睛(第2组)随机分配接受标准小梁切除术。在术后的前3个月内,每当临床评估提示滤过泡即将失败时,两组均进行OM和结膜下注射5-FU(5mg溶于0.5ml平衡盐溶液中)。所有患者均未进行缝线松解。
小梁切除术联合MMC治疗的眼睛随访时间为14至53个月(平均30.17,标准差9.23),小梁切除术治疗的眼睛随访时间为6至54个月(平均27.37,标准差10.83)。在随访的前3个月内,第1组14例和第2组18例进行了OM和结膜下注射5-FU(p=无统计学意义)。第1组14只眼中有14只、第2组18只眼中有14只对OM有阳性反应(p=0.042)。在研究的每个时间间隔,两组术后平均眼压的差异均具有统计学意义(p<0.001)。60只眼中有50只(83.33%)获得成功(完全成功或合格):小梁切除术联合MMC治疗组28只(93.3%),小梁切除术治疗组22只(73.3%)(p=0.039)。在观察到的并发症中,第2组滤过泡纤维化的发生率较高(p=0.0026)。通过术后治疗确定了四个非随机亚组:术中MMC+术后5-FU、术中MMC+术后未用5-FU、术中未用MMC+术后5-FU、术中未用MMC+术后未用5-FU。术中MMC联合术后5-FU治疗的眼睛具有更好的长期(48个月)累积成功概率(100%);单独使用术中MMC或术后5-FU治疗的成功率分别为87.1%和72.2%。仅行小梁切除术后的累积成功概率为56%(p<0.05)。在仅接受术中MMC治疗的亚组中发现1例低眼压性黄斑病变。
本研究证实了术后延迟使用5-FU治疗对有滤过泡失败临床证据患者的有效性和相对安全性。只有当OM导致眼压降低时,晚期结膜下注射5-FU才能有效控制眼压。术中使用MMC可能会确保OM后眼压有更大程度的降低。